他汀类药物使用、心脏放疗剂量与局部晚期肺癌生存
该回顾性分析纳入748例接受胸部放疗的局部晚期非小细胞肺癌(LA-NSCLC)患者,评估他汀治疗与总生存(OS)的关系。
要点
- 高心脏风险LA-NSCLC患者中他汀使用率为51.2%。
- 他汀使用与全因死亡风险增加独立相关,但与主要不良心脏事件无关。
- 未用他汀者心脏平均剂量≥10 Gy与<10 Gy相比死亡风险增加,用他汀者无此差异。
核心结论
- 在LA-NSCLC患者中,他汀使用是全因死亡的独立预测因素,但不是主要不良心脏事件的预测因素。
- 未使用他汀的患者中,较高的平均心脏剂量(≥10 Gy)与全因死亡风险增加相关,而使用他汀的患者中未观察到这一关联。
研究设计与样本
- 回顾性分析748例接受胸部放疗的LA-NSCLC患者,采用Kaplan-Meier法估计OS并使用Cox回归分析。
主要发现
- 高心脏风险患者(Framingham风险≥20%或已有冠心病;n=496)中他汀使用率为51.2%。
临床怎么用
- 对于接受胸部放疗的LA-NSCLC患者,应关注心脏风险及他汀使用情况,但本研究提示他汀使用与全因死亡风险增加相关,需谨慎解读。
- 未使用他汀的患者中,较高的平均心脏剂量(≥10 Gy)与较差的OS相关,提示早期他汀干预可能减轻高心脏放疗剂量的有害效应,但需前瞻性试验验证。
局限性
- 本研究为回顾性分析,可能存在未测量的混杂因素。
- 他汀使用与全因死亡风险增加之间的关联机制尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally advanced non-small cell lung cancer (LA-NSCLC) have a high prevalence of pre-existing coronary heart disease and face excess cardiac risk after thoracic radiation therapy. We sought to assess whether statin therapy is a predictor of overall survival (OS) after thoracic radiation therapy. METHODS AND MATERIALS: We performed a retrospective analysis of 748 patients with LA-NSCLC treated with thoracic radiation therapy, using Kaplan-Meier OS estimates and Cox regression. RESULTS: Statin use among high cardiac risk patients (Framingham risk ≥20% or pre-existing coronary heart disease; n = 496) was 51.2%. After adjustment for baseline cardiac risk and other prognostic factors, statin therapy was associated with a significantly increased risk of all-cause mortality (adjusted hazard ratio, 1.39; 95% confidence interval [CI], 1.00-1.91; P = .048) but not major adverse cardiac events (adjusted hazard ratio, 1.18; 95% CI, 0.52-2.68; P = .69). Among statin-naïve patients, mean heart dose ≥10 Gy versus <10 Gy was associated with a significantly increased risk of all-cause mortality (hazard ratio, 1.32; 95% CI, 1.04-1.68; P = .022), with 2-year OS estimates of 46.9% versus 60.0%, respectively. However, OS did not differ by heart dose among patients on statin therapy (hazard ratio, 1.00; 95% CI, 0.76-1.32; P = 1.00; P-interaction = .031), with 2-year OS estimates of 46.9% versus 50.3%, respectively. CONCLUSIONS: Among patients with LA-NSCLC, only half of statin-eligible high cardiac risk patients were on statin therapy, reflecting the highest cardiac risk level of our cohort. Statin use was an independent predictor of all-cause mortality but not major adverse cardiac events. Elevated mean heart dose (≥10 Gy) was associated with increased risk of all-cause mortality in statin-naïve patients but not among those on statin therapy, identifying a group of patients in which early intervention with statins may mitigate the deleterious effects of high heart radiation therapy dose. This warrants evaluation in prospective trials.
引用
- Atkins KM, Bitterman DS, Chaunzwa TL, et al. Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. Pract Radiat Oncol. 2021. PMID: 33476841. doi:10.1016/j.prro.2020.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。